2018 is here. Now get ready for ‘market-defining’ I-O readouts by Carly Helfand Tuesday, January 2, 2018 If you thought 2017 was a game-changer for immuno-oncology, just wait.
Merck, Incyte IO combo fends off melanoma for 12 months-plus by Tracy Staton Saturday, September 9, 2017 Merck & Co. and Incyte unveiled closely watched data on a one-two punch with Keytruda and the experimental IDO1 inhibitor epacadostat.
BMS loses more ground to Merck as ASCO data stacks up by Carly Helfand Wednesday, June 7, 2017 If Bristol-Myers Squibb needed more evidence to suggest it had lost the immuno-oncology lead to Merck & Co., it got it at ASCO.
Merck, BMS racing again with new Incyte combos by Tracy Staton Monday, April 3, 2017 For a prime illustration of the immuno-oncology cocktail race, look no further than Incyte. It's dancing with four PD-1/PD-L1 inhibitors, and might well take to the floor with a fifth.
